A federal court has reset the ground rules for the 340B program in 2026, and the financial consequences for covered entities are immediate. In American Hospital Association v. Kennedy, the U.S. District Court for the District of Maine vacated the government’s 340B Rebate Model Pilot Program, leaving the long-standing upfront discount structure in place. For hospitals, health centers, and behavioral health providers that build budgets around 340B savings, the ruling removes a near-term cash flow threat but raises new modeling questions that finance teams cannot ignore.
Quick answer: On February 10, 2026, the U.S. District Court for the District of Maine vacated and remanded the 340B Rebate Model Pilot Program after HHS agreed not to defend it, following a December 29, 2025 preliminary injunction and the First Circuit’s January 7, 2026 denial of a stay. As a result, drug manufacturers must continue providing 340B pricing through upfront discounts rather than back-end rebates, preserving covered entities’ working capital while HHS considers whether to restart the process through proper rulemaking.
What the 340B Rebate Pilot Program Tried to Change
HRSA announced the voluntary 340B Rebate Model Pilot Program in 2025. Under the model, approved manufacturers would have charged covered entities the full list price at the point of purchase, then issued a rebate to bring the net cost down to the 340B ceiling price.
The pilot was narrow in scope but significant in principle. It applied only to drugs selected for Medicare price negotiation under the Inflation Reduction Act, reaching nine of the ten products on the first negotiation list, and nine manufacturers received conditional approval to participate.
The mechanical shift from a discount to a rebate sounds technical, but the cash flow effect is not. Under upfront discounts, a 340B entity pays the reduced price immediately and never fronts the difference. Under a rebate model, the entity pays full price first and waits to be repaid, absorbing the financing cost and the collection risk in the interim.
That distinction sits at the center of why hospitals and provider associations sued, and why the court ultimately sided with them. The 340B program has operated on the upfront discount principle for more than thirty years, and a sudden change to the payment sequence would have rewritten budgets that providers had built around predictable, point-of-sale savings.
How Did the Court End the 340B Pilot Program?
The litigation moved quickly. On December 29, 2025, Chief Judge Lance Walker granted a preliminary injunction blocking the pilot before its planned January 1, 2026 effective date, and on January 7, 2026 the First Circuit Court of Appeals denied the government’s request for a stay.
The court’s reasoning rested on the Administrative Procedure Act. As summarized in legal coverage of the ruling, the judge found HHS’s administrative record “threadbare” and concluded the agency had not seriously weighed the rebate model’s impact on entities that had relied on upfront discounts for more than thirty years.
The procedural objection was not a minor technicality. The APA requires agencies to build a reasoned record, consider the consequences of a policy change, and respond to substantive public comments before acting. When a court finds that record inadequate, the practical result is that the policy cannot stand in its current form, regardless of the agency’s underlying goals.
Faced with those rulings, HHS changed course. On February 5, 2026, the agency filed a joint motion conceding that a more complete administrative record was unlikely to change the outcome of the litigation, and asked the court to vacate the program so it could consider a fresh administrative process.
The court granted that request on February 10, 2026, vacating and remanding the pilot notice and the related manufacturer approvals. The American Hospital Association reported that HHS agreed any future effective date would fall no earlier than ninety days after manufacturer applications are approved, signaling that a sudden restart is not on the table.
Why the Outcome Matters for Cash Flow
The headline takeaway for finance leaders is straightforward: nothing changes today. Manufacturers must continue to honor 340B ceiling prices through point-of-sale discounts, so covered entities are not suddenly fronting full list price on expensive specialty drugs.
The avoided harm is meaningful. A rebate model would have forced entities to carry the gap between list price and the 340B price as a receivable, sometimes for weeks, on drugs that can cost thousands of dollars per dose. For a provider dispensing high volumes of negotiated specialty products, that financing burden could have consumed a real share of operating liquidity.
Smaller and safety-net providers would have felt it most acutely. Federally qualified health centers, disproportionate share hospitals, and behavioral health organizations often run on thin margins, and a delayed rebate is harder to absorb than a discount that never required the cash in the first place. Our behavioral health advisory team regularly sees how sensitive these organizations are to timing shifts in reimbursement and drug acquisition cost.
The ruling also protects program integrity in a subtler way. Rebates depend on accurate claims data, audits, and the manufacturer actually paying, each of which introduces leakage and dispute risk that upfront discounts avoid by design. A discount applied at purchase is self-executing, while a rebate is a promise to pay later, and the gap between the two is exactly where reconciliation errors and collection disputes tend to accumulate.
There is also a forecasting benefit to the status quo. Because the discount is fixed at the point of sale, finance teams can project drug acquisition costs with confidence and tie those figures directly to expected reimbursement. A rebate cycle introduces timing uncertainty that complicates both cash forecasting and the monthly close.
What Should Covered Entities Do Now?
The vacatur is a reprieve, not a permanent resolution. HHS has signaled it may pursue a rebate model again through proper notice-and-comment rulemaking, and HRSA issued a Request for Information with a comment period that closed on April 20, 2026 to gather stakeholder input.
Finance and pharmacy leaders should treat the current upfront discount structure as the base case while planning for the possibility of a future rebate model. That means documenting current 340B savings precisely so the organization can quantify exactly what a rebate transition would put at risk.
Several concrete steps are worth taking before any new proposal emerges:
- Model a downside scenario in which negotiated specialty drugs move to a rebate basis, and estimate the working capital required to front those purchases.
- Quantify the days of cash that would be tied up if rebates were paid on a quarterly cycle rather than at the point of sale.
- Review contract pharmacy and 340B software arrangements to confirm they can capture the data a rebate model would demand.
- Stress test covenants and liquidity ratios against a temporary spike in drug-related receivables.
Scenario planning of this kind is where accounting and operational data meet, and it pays to build the model before a rule is final rather than after. Documenting the assumptions now also positions an organization to respond credibly if HHS reopens the comment process, because a provider that has already quantified its exposure can speak to specific dollar figures rather than general concerns.
Pease Bell CPAs helps healthcare organizations connect program-specific reimbursement risk to their broader financial picture, and our advisory services for behavioral health and other providers are built around exactly these forward-looking questions. The goal is not to predict the outcome of the next rulemaking, but to make sure the organization is ready to act on whichever direction it takes.
The strategic point is that the 340B program remains a moving target. The litigation answered the immediate question but left the policy direction open, so the entities that fare best will be those that treat 2026 as a planning year rather than a settled one.
Frequently Asked Questions
Is the 340B Rebate Model Pilot Program still in effect?
No. The U.S. District Court for the District of Maine vacated the pilot on February 10, 2026 after HHS agreed not to defend it. Manufacturers must continue providing 340B pricing through upfront discounts rather than rebates.
Could HHS bring back a 340B rebate model?
Yes. HHS indicated it may pursue a rebate model again through a proper administrative process, and HRSA issued a Request for Information with a comment period that closed on April 20, 2026. Any future model would need a stronger administrative record and would not take effect earlier than ninety days after manufacturer approvals.
Why did the court vacate the pilot program?
The court found that HHS likely violated the Administrative Procedure Act. The judge described the agency’s administrative record as inadequate and concluded HHS had not sufficiently weighed the financial and operational impact on covered entities that had relied on upfront discounts for decades.
How would a rebate model affect a provider’s cash flow?
Under a rebate model, an entity would pay the full list price at purchase and wait to be reimbursed down to the 340B ceiling price. That delay creates a receivable and ties up working capital, a burden that falls hardest on safety-net and behavioral health providers operating on thin margins.
